Trial Profile
Therapeutic effect of transcatheter arterial chemoembolization(TACE) combined with anti-angiogenesis therapy on patients with liver cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Jul 2018 New trial record